Lurbinectedin

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Small Cell Lung Cancer

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (1)
EU
  • Zepzelca, in combination with atezolizumab, is indicated for the maintenance treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed after first-line induction therapy with atezolizumab, carboplatin and etoposide.
Product first approved 2026EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (7)
Small Cell Lung Cancer
NCT06801834 · Gilead Sciences
2025-04-04 – 2029-10 · Extensive Stage Small Cell Lung Cancer (ES-SCLC)
What this study did
NCT06496048 · Luye Pharma Group Ltd.
2024-09-14 – 2028-06-30 · Relapsed Small Cell Lung Cancer
What this study did
Other / comorbidity
NCT06088290 · PharmaMar
2023-09-21 – 2029-08-30 · Leiomyosarcoma
What this study did
Phase 2 (21)
Small Cell Lung Cancer
NCT04607954 · Mayo Clinic
2020-12-04 – 2030-09-02 · Platinum-Resistant Lung Small Cell Carcinoma, Platinum-Sensitive Lung Small Cell Carcinoma, Recurrent Extensive Stage Lung Small Cell Carcinoma, Refractory Extensive Stage Lung Small Cell Carcinoma
What this study did
NCT07459634 · Jazz Pharmaceuticals
2026-10-12 – 2029-11-04 · Extensive-stage Small-cell Lung Cancer
What this study did
NCT05800587 · Fox Chase Cancer Center
2023-02-22 – 2029-08-01 · Lung Cancer, Small-cell Lung Cancer, Non Small Cell Lung Cancer
What this study did
NCT07640932 · Yonsei University
2026-11 – 2029-02 · Carcinoma, Small Cell Lung
What this study did
NCT05578326 · UNC Lineberger Comprehensive Cancer Center
2022-10-12 – 2028-12-25 · Lung Cancer, Small-cell Lung Cancer
What this study did
NCT06501976 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2025-12-31 – 2027-06 · Small Cell Lung Carcinoma
What this study did
NCT06497530 · Guangzhou Institute of Respiratory Disease
2024-12-01 – 2026-12 · Extensive-Stage Small Cell Lung Cancer
What this study did
NCT05572476 · Institut Bergonié
2023-10 – 2024-05-31 · Small Cell Lung Cancer, Platinum-Sensitive Lung Small Cell Carcinoma, Extensive-stage Small-cell Lung Cancer
What this study did
Other / comorbidity
NCT07328425 · Italian Sarcoma Group
2025-11-21 – 2030-10-01 · Desmoplastic Small Round Cell Tumor
What this study did
NCT07121478 · National Cancer Center, Korea
2025-09-23 – 2029-12-31 · Neuroendocrine Tumor of Pancreas, Pancreatic Neuroendocrine Tumors
What this study did
NCT05574504 · AdventHealth
2023-05-08 – 2028-11 · Metastatic Cancer, Urothelial Carcinoma
What this study did
NCT06228066 · National Cancer Institute (NCI)
2024-06-13 – 2028-09-01 · Small Cell Carcinoma of the Bladder, High Grade Neuroendocrine Tumors of the Urinary Tract
What this study did
NCT05229588 · HonorHealth Research Institute
2022-06-14 – 2025-08-04 · Gastrointestinal Malignancies
What this study did
NCT05126433 · Jazz Pharmaceuticals
2022-03-03 – 2023-12-20 · Advanced Solid Tumor, Metastatic Solid Tumor, Urothelial Cancer, Poorly Differentiated Neuroendocrine Carcinomas, Homologous Recombination Deficient-Positive Malignancies Agnostic
What this study did
NCT03213301 · Swiss Cancer Institute
2017-09-28 – 2021-06-11 · Malignant Pleural Mesothelioma, Advanced
What this study did
NCT02448537 · Massachusetts General Hospital
2015-08 – 2019-04-01 · Metastatic Sarcoma
What this study did
NCT01525589 · PharmaMar
2012-06-13 – 2018-10 · Breast Cancer
What this study did
NCT02451007 · PharmaMar
2015-08-12 – 2016-08-19 · Solid Tumors
What this study did
Phase 1/2 (15)
Small Cell Lung Cancer
NCT07141771 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2025-12-31 – 2030-12-31 · SCLC, Extensive Stage
What this study did
NCT07153055 · Misty Shields
2027-01 – 2029-10 · Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer
What this study did
NCT05652686 · Phanes Therapeutics
2023-09-05 – 2028-08 · Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC), Neuroendocrine Prostate Cancer (NEPC), Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC), Neuroendocrine Carcinomas (NEC), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)
What this study did
NCT04802174 · National Cancer Institute (NCI)
2021-06-01 – 2027-12-01 · SCLC, Small Cell Cancer, Advanced Solid Tumor, High Grade Neuroendocrine Cancers
What this study did
NCT02611024 · PharmaMar
2016-05-06 – 2025-07-01 · Advanced Solid Tumors, Glioblastoma, Soft Tissue Sarcoma (Excluding GIST), Endometrial Carcinoma, Epithelial Ovarian Carcinoma, Mesothelioma, Gastroenteropancreatic Neuroendocrine Tumor, SCLC, Gastric Carcinoma, Pancreatic Adenocarcinoma, Colorectal Carcinoma, Neuroendocrine Tumors
What this study did
NCT04358237 · Antonio Calles Blanco
2020-09-21 – 2025-05-20 · Small Cell Lung Carcinoma
What this study did
NCT04253145 · Fundacion Oncosur
2019-12-13 – 2025-05 · Carcinoma, Small Cell Lung
What this study did
Other / comorbidity
NCT05918640 · Children's Hospital of Philadelphia
2023-07-27 – 2029-07-30 · Ewing Sarcoma, Desmoplastic Small Round Cell Tumor, Pediatric Cancer, Undifferentiated Sarcoma
What this study did
NCT05099666 · Massachusetts General Hospital
2022-02-04 – 2028-07 · Advanced Soft-tissue Sarcoma, Metastatic Soft-tissue Sarcoma, Advanced Leiomyosarcoma, Leiomyosarcoma Metastatic
What this study did
NCT05734066 · Jazz Pharmaceuticals
2023-05-23 – 2028-04-20 · Refractory Ewing Sarcoma, Relapsed Ewing Sarcoma, Ewing Sarcoma
What this study did
NCT06217536 · University of California, San Francisco
2024-10-31 – 2027-10-31 · Locally Advanced Soft Tissue Sarcoma
What this study did
NCT05876715 · ERLINDA M GORDON
2023-06-07 – 2026-09-30 · Advanced Soft-tissue Sarcoma
What this study did
NCT06385548 · Vall d'Hebron Institute of Oncology
2024-05 – 2026-04 · Endometrial Cancer
What this study did
NCT05042934 · M.D. Anderson Cancer Center
2021-09-15 – 2022-08-30 · Metastatic Ewing Sarcoma, Recurrent Ewing Sarcoma
What this study did
NCT02684318 · Poveda, Andrés, M.D.
2015-07 – 2019-10 · Advanced Cancer, Ovarian Cancer, Endometrial Cancer, Breast Cancer
What this study did
Phase 1 (15)
Small Cell Lung Cancer
NCT05244239 · Emory University
2022-07-27 – 2027-07-28 · Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
What this study did
NCT04610658 · H. Lee Moffitt Cancer Center and Research Institute
2020-11-23 – 2023-03-24 · Small-cell Lung Cancer, Relapsed Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer
What this study did
NCT01970540 · PharmaMar
2011-05-25 – 2017-08-09 · Endometrial Adenocarcinomas, Neuroendocrine Tumors, Small-cell Lung Cancer With Less Than 2 Prior Cytotoxic-containing Lines of Therapy
What this study did
NCT01831089 · PharmaMar
2013-09 – 2016-07 · Breast Cancer, Ovarian Cancer, Gynecological Cancer, Head and Neck Carcinoma, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Non-squamous Cell Lung Cancer
What this study did
Other / comorbidity
NCT05636111 · M.D. Anderson Cancer Center
2023-07-12 – 2026-12-31 · Ovarian Cancer
What this study did
NCT05101265 · PharmaMar
2021-03-09 – 2025-06-01 · Advanced Solid Tumor, Hepatic Impairment
What this study did
NCT04638491 · Luye Pharma Group Ltd.
2020-11-24 – 2023-11-04 · Advanced Solid Tumor
What this study did
NCT05063318 · PharmaMar
2020-10-07 – 2022-04-21 · Advanced Solid Tumors
What this study did
NCT05072106 · PharmaMar
2021-01-14 – 2022-01-18 · Advanced Solid Tumor
What this study did
NCT01980667 · PharmaMar
2014-07-30 – 2017-01-05 · Advanced Solid Tumors
What this study did
NCT02210364 · PharmaMar
2013-04 – 2016-10 · Metastatic Breast Cancer, Pancreatic Cancer, Metastatic Colorectal Cancer
What this study did
NCT01405391 · PharmaMar
2011-11 – 2016-01 · Major Advanced Solid Tumors Other Than Colorectal
What this study did
NCT01314599 · PharmaMar
2011-05 – 2015-07 · Acute Leukemia
What this study did
NCT01970553 · PharmaMar
2011-05 – 2013-10 · Specific Advanced Solid Tumors
What this study did
NCT00877474 · PharmaMar
2009-03 – 2011-06 · ADVANCED SOLID TUMORS
What this study did
Used as active comparator (7)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (6)
Small Cell Lung Cancer
NCT07947121 · GlaxoSmithKline
2026-12-25 – 2032-03-24 · Lung Neoplasm
What this study did
NCT07625644 · SystImmune Inc.
2026-08-04 – 2031-06 · Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer, Small Cell Carcinoma, Sclc, SCLC,Extensive Stage, Lung Cancer, Lung Cancer Metastatic, Lung Cancer Stage IV
What this study did
NCT06203210 · Daiichi Sankyo
2024-05-21 – 2029-12-01 · Small Cell Lung Cancer
What this study did
NCT05740566 · Amgen
2023-05-31 – 2028-03-26 · Small Cell Lung Cancer (SCLC)
What this study did
Phase 1/2 (1)
Small Cell Lung Cancer
NCT06681220 · VA Office of Research and Development
2026-02-23 – 2030-12-31 · Relapsed Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 2 (1)
Small Cell Lung Cancer
NCT07258147 · Sichuan University
2026-10-31 – 2028-12-30 · Lung Cancer (SCLC)
What this study did

Competitive landscape

This drug's own stage for Small Cell Lung Cancer: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Lurbinectedin: this drugApprovedSmall moleculeAlkylating DrugPartial signalNo reviewed efficacy summary in this indication
AtezolizumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
DurvalumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
TarlatamabApprovedMultispecific antibodyDLL3 and CD3Partial signal
NCT06211036: Primary endpoint, overall survival: met at a pre-specified interim analysis (Amgen, 2026-09-08).
NCT05740566: Overall survival: median 13.6 months (95% CI 11.1 to not reached) vs 8.3 months (95% CI 7.0 to 10.2) on chemotherapy; stratified hazard ratio for death 0.60 (DeLLphi-304, NEJM 2025).
Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs)ApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
ABBV-706Phase 3Antibody–drug conjugateSEZ6not yet gradedNo reviewed efficacy summary in this indication
AdebrelimabPhase 3Monoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
AL8326Phase 3Small moleculeAurora B / FGFR / VEGFR (multi-kinase)Weak signal
NCT04890795: ORR 20% (6/30, 4 confirmed responses); median PFS 3.65 months; median OS 10.42 months in 30 evaluable ≥3rd-line SCLC patients (data cutoff Nov 30, 2022)
AtigotatugPhase 3Monoclonal antibody—not yet gradedNo reviewed efficacy summary in this indication
GocatamigPhase 3Multispecific antibody—not yet gradedNo reviewed efficacy summary in this indication
Ifinatamab DeruxtecanPhase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
ObrixtamigPhase 3Multispecific antibodyDLL3 (Delta-like ligand 3) x CD3not yet gradedNo reviewed efficacy summary in this indication
PumitamigPhase 3Multispecific antibodyPD-L1 and VEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Risvutatug RezetecanPhase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
SerplulimabPhase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Tambotatug PelitecanPhase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
TislelizumabPhase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
AlisertibPhase 2Small moleculeAurora kinase A (AURKA)not yet gradedNo reviewed efficacy summary in this indication
BMS-986525Phase 1/2Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
DJI136Phase 1/2Cell therapyDLL3not yet gradedNo reviewed efficacy summary in this indication
Quaratusugene Ozeplasmid (Reqorsa)Phase 1/2Gene therapy / editingTUSC2 (tumor suppressor gene replacement)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(20 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Lurbinectedin to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (5)
December 2026 (5)
Phase 1/2Advanced Soft-tissue Sarcoma, Metastatic Soft-tissue Sarcoma, Advanced Leiomyosarcoma, Leiomyosarcoma MetastaticActive not recruiting
Est. primary completion 2026-12 · NCT05099666 · CT.gov ↗
What to watch
Phase 2Small Cell Lung CancerRecruiting
Est. primary completion 2026-12 · NCT06497530 · CT.gov ↗
What to watch
Phase 2Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-12 · NCT06501976 · CT.gov ↗
What to watch
Phase 2Small Cell Lung CancerRecruiting
Est. primary completion 2026-12-25 · NCT05578326 · CT.gov ↗
What to watch
Phase 1Ovarian CancerRecruiting
Est. primary completion 2026-12-31 · NCT05636111 · CT.gov ↗
What to watch
2027 (5)
March 2027 (1)
Phase 2Neuroendocrine Tumor of Pancreas, Pancreatic Neuroendocrine TumorsEnrolling by invitation
Est. primary completion 2027-03-01 · NCT07121478 · CT.gov ↗
What to watch
April 2027 (1)
Phase 2Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-04 · NCT07640932 · CT.gov ↗
What to watch
September 2027 (1)
Phase 2Small Cell Carcinoma of the Bladder, High Grade Neuroendocrine Tumors of the Urinary TractRecruiting
Est. primary completion 2027-09-01 · NCT06228066 · CT.gov ↗
What to watch
December 2027 (2)
Phase 1/2Small Cell Lung CancerRecruiting
Est. primary completion 2027-12 · NCT05652686 · CT.gov ↗
What to watch
Phase 3Small Cell Lung CancerRecruiting
Est. primary completion 2027-12-31 · NCT06496048 · CT.gov ↗
What to watch
2028 (3)
January 2028 (1)
Phase 1/2Refractory Ewing Sarcoma, Relapsed Ewing Sarcoma, Ewing SarcomaRecruiting
Est. primary completion 2028-01-28 · NCT05734066 · CT.gov ↗
What to watch
July 2028 (1)
Phase 1/2Ewing Sarcoma, Desmoplastic Small Round Cell Tumor, Pediatric Cancer, Undifferentiated SarcomaRecruiting
Est. primary completion 2028-07-30 · NCT05918640 · CT.gov ↗
What to watch
August 2028 (1)
Phase 2Small Cell Lung CancerRecruiting
Est. primary completion 2028-08-01 · NCT05800587 · CT.gov ↗
What to watch
2029 (5)
April 2029 (2)
Phase 1/2Small Cell Lung CancerRecruiting
Est. primary completion 2029-04 · NCT07153055 · CT.gov ↗
What to watch
Phase 2Small Cell Lung CancerRecruiting
Est. primary completion 2029-04 · NCT07155174 · CT.gov ↗
What to watch
August 2029 (2)
Phase 2Small Cell Lung CancerRecruiting
Est. primary completion 2029-08-04 · NCT07459634 · CT.gov ↗
What to watch
Phase 3LeiomyosarcomaActive not recruiting
Est. primary completion 2029-08-30 · NCT06088290 · CT.gov ↗
What to watch
October 2029 (1)
Phase 3Small Cell Lung CancerRecruiting
Est. primary completion 2029-10 · NCT06801834 · CT.gov ↗
What to watch
2030 (2)
June 2030 (1)
Phase 1/2Small Cell Lung CancerNot yet recruiting
Est. primary completion 2030-06-30 · NCT07141771 · CT.gov ↗
What to watch
October 2030 (1)
Phase 2Desmoplastic Small Round Cell TumorRecruiting
Est. primary completion 2030-10-01 · NCT07328425 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(6)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

30 September 2026WithdrawalFDA approves voluntary withdrawal of the Zepzelca second-line SCLC accelerated approval indication
US, FDA · Jazz Pharmaceuticals Ireland, Ltd. · Source ↗
June 2026Topline resultPhase 3 LAGOON did not meet its overall survival primary endpoint
7 October 2025FDA action datePDUFA date set for Zepzelca plus atezolizumab
US, FDA · Source ↗
2 October 2025ApprovalFDA approves Zepzelca plus atezolizumab as first-line maintenance for ES-SCLC
US, FDA · Source ↗
10 June 2025Filing acceptedFDA accepts sNDA for Zepzelca plus atezolizumab
US, FDA · Source ↗
10 June 2025Priority reviewFDA grants Priority Review to Zepzelca plus atezolizumab sNDA
US, FDA · Source ↗